オミクロン株対応ワクチンの効能・効果、用法・用量の一部変更承認について｜厚生労働省
https://www.mhlw.go.jp/stf/newpage_27929.htmlオミクロン株対応ワクチンの効能・効果、用法・用量の一部変更承認について｜厚生労働省
Open the dedicated viewer to inspect the saved page with archive metadata pinned above it, similar to archive wrappers such as Web Gyotaku.
This is a self-contained HTML copy with CSS and images embedded, so it still renders even if the original page disappears.
The dedicated viewer keeps the original URL and saved timestamp visible while you review the archived HTML.
This page announces the approval of partial changes to the efficacy, effects, usage, and dosage of Omicron variant-adapted vaccines by Japan's Ministry of Health, Labour and Welfare on September 12, 2022. Pfizer's "Comirnaty RTU" and Moderna's "Spikevax" vaccines have been approved for expanded use to include formulations containing mRNA encoding spike proteins of both the original strain and Omicron variant. Both vaccines are approved for booster immunization, with a minimum interval of 5 months between doses, though future shortening of this interval is being considered.
